Theravance soars on mostly positive Breo review
This article was originally published in Scrip
Executive Summary
Shares of Theravance rocketed 25% on 15 April on a mostly positive review from the US FDA for Breo (fluticasone furoate/vilanterol), although regulators raised some concerns about an increased risk of pneumonia and fractures with the experimental chronic obstructive pulmonary disease (COPD) medicine.